Hodgkin lymphoma |
hsa-miR-17 |
Hodgkin Reed Sternberg cells |
Up |
CDKN1A |
Overexpression of hsa-miR-17 is associated with dysfunctional p53 signaling pathway and also to malignant phenotype in Hodgkin lymphoma. |
Gibcus et al., 2011 |
Hodgkin lymphoma |
hsa-miR-106b |
Hodgkin Reed Sternberg cells |
Up |
CDKN1A |
Overexpression of hsa-miR-106b is associated with dysfunctional p53 signaling pathway and also to malignant phenotype in Hodgkin lymphoma. |
Gibcus et al., 2011 |
Chronic lymphocytic leukemia |
hsa-miR-132 |
Peripheral blood |
Up |
SIRT1 |
Up-regulation of hsa-miR-132 down-regulates the expression of SIRT1 and induces TP53-dependent apoptosis in chronic lymphocytic leukemia. |
Dal et al., 2015 |
B-cell chronic lymphocytic leukemia |
hsa-miR-15a |
Peripheral blood |
Down |
TP53 |
Over-expression of hsa-miR-15a suppresses the expression of TP53 in B-cell chronic lymphocytic leukemia. A microRNA/TP53 feedback circuitry is associated with chronic lymphocytic leukemia pathogenesis. |
Fabbri et al, 2011 |
B-cell chronic lymphocytic leukemia |
hsa-miR-16-1 |
Peripheral blood |
Down |
TP53 |
Over-expression of hsa-miR-16-1 suppresses the expression of TP53 in B-cell chronic lymphocytic leukemia. A microRNA/TP53 feedback circuitry is associated with chronic lymphocytic leukemia pathogenesis. |
Fabbri et al, 2011 |
Chronic lymphocytic leukemia |
hsa-miR-34a |
Peripheral blood |
Up |
|
MicroRNA-34a is proposed as a marker for the activity of the p53 signaling pathway in chronic lymphocytic leukemia. |
Merkel et al., 2010 |
Gastric cancer |
hsa-miR-100 |
Gastric cancer tissue |
Up |
|
MicroRNA-100 antagonism suppresses ubiquitin-mediated p53 protein degradation by activating RNF144B, an E3 ubiquitination ligase. |
Yang et al., 2016 |
Gastric cancer |
hsa-miR-18a |
Stomach |
Up |
IRF2 |
MicroRNA-18a regulates the expression of P53 by directly targeting IRF2 in gastric cancer. |
Chen et al., 2016 |
Gastric cancer |
hsa-miR-149 |
AGS, MKN-28, MKN-45 |
Down |
ZBTB2 |
MicroRNA-149 acts as a tumor suppressor through down-regulating ZBTB2 in human gastric cancer. |
Wang et al., 2012 |
Gastric cancer |
hsa-miR-449 |
SNU-638 |
Down |
|
MicroRNA-449 promotes senescence and apoptosis through activating the p53 signaling pathway. |
Bou et al., 2011 |
Hepatocellular carcinoma |
hsa-miR-21 |
Hep-G2 |
Up |
HBP1 |
MicroRNA-21 induces hepatocellular carcinoma progression through targeting Hbp1-p53-Srebp1c pathway. |
Wu et al., 2015 |
Non-alcoholic fatty liver disease |
hsa-miR-21 |
Hep-G2 |
Up |
HBP1 |
MicroRNA-21 induces hepatic lipid accumulation through targeting Hbp1-p53-Srebp1c pathway. |
Wu et al., 2015 |
Non-alcoholic fatty liver disease |
hsa-miR-21 |
Hep-G2 |
Up |
HBP1 |
Downregulation of hsa-miR-21 increases expression of HBP1 and p53 and decreased lipogenesis. miR-21 stimulates hepatic lipid accumulation and cancer development through modulation of Hbp1-p53-Srebp1c pathway. |
Wu et al., 2015 |
Gastric cancer |
hsa-miR-18a |
Stomach |
Up |
IRF2 |
Overexpression of hsa-miR-18a downregulates the expression of IRF2. Mir-18a modulates p53 expression by targeting IRF2 and regulates p53 signaling in gastric cancer. |
Chen et al., 2016 |
Hepatocellular carcinoma |
hsa-miR-205 |
Hepatocyte |
Up |
USP7 |
Overexpression of hsa-miR-205 represses the expression of USP7. Mir-205 modulates p53 signaling pathway and cell proliferation levels in hepatocellular carcinoma cell. |
Zhu et al., 2015 |
Hepatocellular carcinoma |
hsa-miR-1246 |
Hepatocyte |
|
NFIB |
p53 controls the expression of hsa-miR-1246 in hepatocellular carcinoma. hsa-miR-1246 directly targets nuclear factor I/B (NFIB). Overexpression of hsa-miR-1246 promotes cell proliferation, colony formation and apoptosis through modulating p53 signaling pathway in hepatocellular carcinoma. |
Zhang et al., 2015 |
Ovarian cancer |
hsa-miR-17 |
Ovary |
|
LKB1 |
hsa-miR-17 regulates proliferation and invasion of ovarian tumor cells via targeting LKB1-p53-p21/WAF1 pathway. |
Liu et al., 2015 |
Prostate cancer |
hsa-miR-340 |
DU145, BPH-1, PC-3 |
Down |
MDM2 |
MicroRNA-340 acts as a tumor suppressor via the p53 signaling pathway by inhibiting MDM2 expression in prostate cancer. |
Huang et al., 2016 |
Bladder cancer |
hsa-miR-155 |
UM-UC-3, T24 |
Up |
DMTF1 |
MicroRNA-155 acts as a tumor promoter by inhibiting DMTF1 expression in bladder cancer. |
Peng et al., 2015 |